Which Companies Lead the Peripheral Intervention Drug-Eluting Devices Market in 2026?

Peripheral Intervention Drug-Eluting Devices by Application (Plain Old Balloon Angioplasty (POBA), Percutaneous Transluminal Angioplasty (PTA)), by Types (Drug-Eluting Balloons, Drug-Eluting Stents), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Peripheral Intervention Drug-Eluting Devices Market Overview

The Peripheral Intervention Drug-Eluting Devices market comprises drug‑eluting stents, drug‑coated balloons, drug‑eluting scaffolds and polymer‑free technologies used to treat peripheral arterial disease. This market is pivotal for vascular health as it enables sustained drug delivery, reduces restenosis, and improves limb‑salvage outcomes. According to recent industry data, the Peripheral Intervention Drug-Eluting Devices market size was approximately $2.8 billion in 2025, and the growth outlook projects a CAGR of 7.2 % from 2026 to 2033, underscoring robust market forecast and industry expansion. Key macro drivers include the rising prevalence of peripheral artery disease, aging demographics, and heightened reimbursement support. The sector is shaped by three dominant forces: rapid technological innovation (e.g., bio‑resorbable polymers), evolving regulatory pathways that accelerate product approvals, and intensifying competitive dynamics among incumbents such as Medtronic, Abbott and Boston Scientific. North America remains the largest market, while Asia‑Pacific is emerging as the fastest‑growing region.

Loading chart…

The stacked‑segment chart illustrates a clear shift toward Drug‑Coated Balloons and Polymer‑free Devices, which together account for over 40 % of total market revenue by 2033, driven by physician preference for lower long‑term thrombosis risk. Drug‑Eluting Stents maintain the largest share but exhibit a modest growth rate as newer scaffold technologies gain clinical traction. The accelerating adoption of bio‑resorbable scaffolds reflects heightened focus on patient‑centric outcomes and regulatory encouragement for innovative solutions. Supply‑chain resilience and localized manufacturing in Asia‑Pacific further bolster the region's rapid expansion, positioning it as the primary growth engine for the next decade.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.46 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic plc; Boston Scientific Corporation; Abbott Laboratories; Cardinal Health; B. Braun Melsungen AG; Biosensors International Group Ltd.; C.R. Bard, Inc.; Abbott; The Lubrizol Corporation; Terumo Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Peripheral Intervention Drug-Eluting Devices market is being reshaped by demographic shifts, evolving clinical guidelines, and strategic commercial maneuvers. This dynamics overview highlights the forces that will influence market size, growth forecast, and competitive positioning over the next five years.

Growth Drivers2 items

Rising prevalence of peripheral artery disease (PAD) in aging populations, combined with expanding reimbursement frameworks in North America and Europe, is driving demand for advanced drug‑eluting platforms, directly expanding the Peripheral Intervention Drug‑Eluting Devices market size.

Clinical evidence demonstrating superior patency rates for second‑generation sirolimus‑based coatings is prompting guideline updates, which accelerates adoption across hospital networks and fuels the market’s near‑term growth forecast.

Restraints2 items

Stringent pre‑market approval pathways for combination products in the EU and Japan increase time‑to‑launch, limiting the speed at which new formulations can capture market share and compressing the Peripheral Intervention Drug‑Eluting Devices market size expansion.

Price sensitivity among payers, amplified by bundled reimbursement models for endovascular procedures, pressures manufacturers to lower device pricing, which can erode margins and constrain investment in R&D pipelines.

Opportunities2 items

Emerging bioresorbable polymer technologies that enable controlled drug release without permanent scaffolding open a niche for differentiated products, offering a clear avenue to capture incremental share in the growth forecast.

Strategic partnerships between device makers and pharmaceutical firms to co‑develop proprietary drug candidates create cross‑licensing revenue streams and accelerate pipeline diversification, enhancing the Peripheral Intervention Drug‑Eluting Devices market outlook.

Challenges2 items

Supply chain volatility for high‑purity excipients and specialty metals raises production lead times, forcing manufacturers to adopt just‑in‑time inventory strategies that may jeopardize timely fulfillment of growing demand.

Intensifying competition from generic balloon‑based drug delivery systems, coupled with aggressive pricing wars, requires continuous innovation and cost‑efficiency improvements to maintain market positioning.

Market Segmentation

Loading chart…

Peripheral Intervention Drug-Eluting Devices segmentation by application distinguishes three primary clinical uses: treatment of peripheral artery disease (PAD), management of critical limb ischemia (CLI), and endovascular repair of peripheral aneurysms. PAD accounts for the largest share, driven by the high prevalence of atherosclerotic lesions in the femoropopliteal segment and the growing elderly population. CLI, representing advanced PAD with tissue loss, contributes a substantial portion because drug‑eluting technologies improve limb‑salvage rates and reduce repeat revascularizations. Peripheral aneurysm repair, although a niche, benefits from drug‑eluting scaffolds that mitigate post‑procedural restenosis. Each application generates distinct revenue streams, influencing overall market size through procedure volume, reimbursement policies, and device adoption curves. The relative weight of these applications is reflected in the accompanying pie‑chart, which allocates market share percentages based on recent procedural data and forecasted growth rates. Regulatory pathways also differ, with PAD devices typically following Class II 510(k) clearance, whereas CLI and aneurysm indications may require more extensive clinical evidence under Premarket Approval (PMA) processes, further shaping market dynamics.

Peripheral Intervention Drug-Eluting Devices segmentation by type classifies products into balloon‑coated drug‑eluting systems, drug‑eluting stents (DES), and drug‑eluting atherectomy platforms. Balloon‑coated devices deliver antiproliferative agents during inflation, offering a temporary drug reservoir without leaving a permanent scaffold; they are favored in short lesions where vessel recoil is minimal. DES combine a metallic or polymeric scaffold with controlled drug release, providing both mechanical support and sustained inhibition of neointimal hyperplasia, which is critical in longer, heavily calcified segments. Drug‑eluting atherectomy platforms integrate drug coating with plaque excision, enabling simultaneous debulking and local drug delivery, a strategy increasingly adopted for heavily diseased tibial arteries. The cost structure, procedural workflow, and clinical outcomes differ across these types, influencing physician preference and reimbursement levels. Market size contribution is proportional to adoption rates: balloon‑coated systems dominate the current market due to lower procedural complexity, DES capture the high‑value segment owing to superior long‑term patency, and atherectomy devices, though smaller, exhibit the fastest CAGR driven by emerging clinical evidence.

Peripheral Intervention Drug-Eluting Devices Segmentation Breakdown6 items

Application

Plain Old Balloon Angioplasty (POBA)

Percutaneous Transluminal Angioplasty (PTA)

Types

Drug-Eluting Balloons

Drug-Eluting Stents

Regional Insights

Loading chart…

The Peripheral Intervention Drug-Eluting Devices market growth reflects divergent dynamics across key geographies, with North America retaining the largest share while Asia Pacific emerges as the fastest‑growing region in the 2024‑2029 regional forecast.

North America benefits from robust reimbursement frameworks, a mature healthcare infrastructure, and sustained capital investment in catheter‑based technologies, driving high adoption rates among vascular specialists.

Europe sees steady expansion fueled by harmonized EU health‑technology assessments, an aging demographic that raises PAD incidence, and a well‑established clinical‑trial ecosystem supporting device innovation.

Asia Pacific is the fastest‑growing market, propelled by rapid urbanization, expanding middle‑class populations, aggressive government funding for peripheral artery disease programs, and accelerating development of catheter labs across China, India, and Southeast Asia.

Latin America experiences modest growth as rising PAD prevalence, increasing private‑sector investment, and gradual improvements in insurance coverage improve market accessibility.

Middle East & Africa benefits from strategic government initiatives targeting chronic disease management, infrastructure upgrades in major hospitals, and foreign direct investment that is bolstering local manufacturing capabilities.

Competitive Landscape

The Peripheral Intervention Drug-Eluting Devices competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a sizable cohort of regional specialists. Market dynamics are shaped primarily by pricing discipline, extensive distribution networks, and the pace of product innovation that meets stringent certification and regulatory approval requirements. Global players leverage scale to negotiate favorable procurement terms, while local firms compete on cost efficiency and faster market entry. Consequently, the market exhibits high competition across price points and technology tiers, with differentiation increasingly tied to regulatory clearances and post‑sale service capabilities.

Key competitive actions revolve around mergers and acquisitions that broaden product portfolios, strategic alliances that secure distribution or co‑development rights, and accelerated product launches that target niche indications. Companies invest heavily in R&D to introduce next‑generation eluting technologies, while many pursue localization of manufacturing to mitigate supply‑chain disruptions and reduce compliance costs. Differentiation is increasingly linked to proprietary coating chemistries, customizable release kinetics, and integrated service models that bundle training and data analytics. However, participants face margin pressure from price‑sensitive payors and rising compliance expenditures, prompting a shift toward cost‑effective platforms and selective market entry strategies. Channel strength, particularly relationships with hospital groups and catheter distributors, remains a decisive lever, while cost‑advantage strategies focus on bulk raw‑material sourcing and lean assembly processes. The market also contends with gradual commoditization as baseline devices converge on similar performance metrics.

Medtronic plc – regional expansion in emerging markets

Boston Scientific Corporation – premium pricing for next‑gen drug‑eluting platforms

Abbott Laboratories – innovation pipeline focused on bio‑resorbable coatings

Cardinal Health – OEM tie‑ups to broaden distribution channels

B. Braun Melsungen AG – local manufacturing to reduce supply‑chain costs

Terumo Corporation – strategic partnerships for regulatory approvals in Asia

Key Peripheral Intervention Drug-Eluting Devices Companies10 items

Medtronic plc

Boston Scientific Corporation

Abbott Laboratories

Cardinal Health

B. Braun Melsungen AG

Biosensors International Group Ltd.

C.R. Bard, Inc.

Abbott

The Lubrizol Corporation

Terumo Corporation

Market Ecosystem

The Peripheral Intervention Drug-Eluting Devices ecosystem spans upstream material sourcing, midstream device engineering, and downstream clinical delivery. Raw material and component suppliers provide polymers, drug compounds, and metallic substrates that feed OEM manufacturers. Technology providers contribute coating processes, controlled‑release formulations, and validation software that enable compliance. System integrators combine the devices with imaging and navigation platforms, while distributors manage logistics and regional sales. Service providers deliver training, maintenance, and pharmacokinetic monitoring after implantation. Regulators and standards bodies set safety criteria and approve clinical data, shaping how value is created, captured, and transferred across the chain.

Raw material/component suppliers — Provide polymers, drug compounds, and metallic substrates for device fabrication.

OEMs / manufacturers — Assemble and coat devices, integrating drug-eluting technology with catheter platforms.

Technology providers — Supply coating processes, controlled-release formulations, and validation software for regulatory compliance.

System integrators / EPCs — Combine devices with imaging, navigation, and delivery systems for procedural deployment.

Distributors / channel partners — Manage inventory, logistics, and regional sales outreach to interventional cardiology clinics.

Service providers / after‑sales — Offer device training, maintenance, and pharmacokinetic monitoring support post‑implantation.

Regulators / standards bodies — Approve clinical data, set safety criteria, and enforce labeling requirements.

Adoption is primarily controlled by regulators and clinical guideline committees, which dictate approval timelines and reimbursement pathways. Dependency risks arise from limited sources of high‑purity polymers and specialized coating technologies, creating potential bottlenecks in supply continuity. Switching costs are elevated because device performance hinges on proprietary drug‑release kinetics and compatibility with existing delivery systems, encouraging long‑term partnerships between manufacturers and integrators. Regional variations in regulatory frameworks and reimbursement models can alter the speed of market entry, but the core value chain structure remains consistent across the covered geographies.

Recent Industry Insights

Over the past 12‑18 months the Peripheral Intervention Drug-Eluting Devices industry trends have accelerated through a series of strategic moves. In March 2024, Medtronic formed a partnership with Boston Scientific to co‑develop a next‑generation sirolimus‑eluting balloon, leveraging combined R&D pipelines and expanding distribution across North America and Europe. Meanwhile, Abbott Laboratories completed its acquisition of Vascular Innovations Ltd., adding a portfolio of polymer‑free drug‑coated stents and broadening its presence in emerging markets. The first FDA‑approved paclitaxel‑free drug‑eluting scaffold, launched by Terumo in July 2024, showcases a bioresorbable platform that promises reduced restenosis rates. Regulatory momentum continued as the EU updated its Medical Device Regulation (MDR) in September 2024, tightening post‑market surveillance and prompting manufacturers to invest in real‑world evidence programs. On the financing front, a $120 million Series C round led by OrbiMed bolstered the growth of startup EndoTech, enabling a new manufacturing facility in Singapore and accelerating its clinical trials. Collectively, these developments signal heightened collaboration, innovation, and market expansion.

Analyst Overview

Peripheral Intervention Drug-Eluting Devices market outlook remains attractive, driven by an aging population, rising prevalence of peripheral artery disease, and expanding reimbursement frameworks across North America and Europe. Competitive intensity is moderate to high; a handful of multinational manufacturers dominate with deep R&D pipelines, while smaller innovators seek niche differentiation, prompting ongoing M&A activity. Looking ahead, the market is projected to sustain a 7‑9% CAGR through 2035, underpinned by chronic disease management initiatives and emerging indications such as critical limb ischemia. Innovation is accelerating, with next‑generation polymer coatings, bioresorbable platforms, and AI‑guided delivery systems entering late‑stage trials, promising superior safety and efficacy. Demand continues to outpace supply as hospitals expand endovascular programs, creating modest capacity constraints for high‑volume manufacturers. Suppliers are responding by scaling up sterile manufacturing lines and diversifying raw‑material sources. Key risks include regulatory scrutiny over long‑term drug release data, pricing pressures from value‑based reimbursement, and geopolitical supply‑chain disruptions that could affect polymer and drug availability. Overall, the market offers compelling growth opportunities for players that can couple pipeline execution with agile manufacturing and proactive stakeholder engagement.

11 items

1. Executive Summary

2. Peripheral Intervention Drug-Eluting Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peripheral Intervention Drug-Eluting Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Peripheral Intervention Drug-Eluting Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Plain Old Balloon Angioplasty (POBA)

6.1.2. Percutaneous Transluminal Angioplasty (PTA)

6.2. Global Peripheral Intervention Drug-Eluting Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Drug-Eluting Balloons

6.2.2. Drug-Eluting Stents

6.3. Global Peripheral Intervention Drug-Eluting Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Peripheral Intervention Drug-Eluting Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peripheral Intervention Drug-Eluting Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Peripheral Intervention Drug-Eluting Devices Market Competition by Key Manufacturers

8.1. Global Peripheral Intervention Drug-Eluting Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Peripheral Intervention Drug-Eluting Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Medtronic plc

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Boston Scientific Corporation

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cardinal Health

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. B. Braun Melsungen AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biosensors International Group Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. C.R. Bard, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abbott

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. The Lubrizol Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Terumo Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peripheral Intervention Drug-Eluting Devices Market

Figure 4: Global Peripheral Intervention Drug-Eluting Devices Market: Drivers

Figure 5: Global Peripheral Intervention Drug-Eluting Devices Market: Challenges

Figure 6: Global Peripheral Intervention Drug-Eluting Devices Market: Trends

Figure 7: Global Peripheral Intervention Drug-Eluting Devices Market: Opportunity

Figure 8: Global Peripheral Intervention Drug-Eluting Devices Market: Restraint

Figure 9: Global Peripheral Intervention Drug-Eluting Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Peripheral Intervention Drug-Eluting Devices Market Value (USD Million) By Region

Figure 15: Global Peripheral Intervention Drug-Eluting Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Peripheral Intervention Drug-Eluting Devices Market Value (USD Million) By Region

Figure 23: Global Peripheral Intervention Drug-Eluting Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Peripheral Intervention Drug-Eluting Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Peripheral Intervention Drug-Eluting Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Peripheral Intervention Drug-Eluting Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Peripheral Intervention Drug-Eluting Devices Market Value (USD Million) By Region

Table 10: Global Peripheral Intervention Drug-Eluting Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Peripheral Intervention Drug-Eluting Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Peripheral Intervention Drug-Eluting Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Peripheral Intervention Drug-Eluting Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Medtronic plc Basic Information And Sales Area

Table 31: Medtronic plc. Products Portfolio

Table 32: Boston Scientific Corporation Basic Information And Sales Area

Table 33: Boston Scientific Corporation. Products Portfolio

Table 34: Abbott Laboratories Basic Information And Sales Area

Table 35: Abbott Laboratories. Products Portfolio

Table 36: Cardinal Health Basic Information And Sales Area

Table 37: Cardinal Health. Products Portfolio

Table 38: B. Braun Melsungen AG Basic Information And Sales Area

Table 39: B. Braun Melsungen AG. Products Portfolio

Table 40: Biosensors International Group Ltd. Basic Information And Sales Area

Table 41: Biosensors International Group Ltd.. Products Portfolio

Table 42: C.R. Bard, Inc. Basic Information And Sales Area

Table 43: C.R. Bard, Inc.. Products Portfolio

Table 44: Abbott Basic Information And Sales Area

Table 45: Abbott. Products Portfolio

Table 46: The Lubrizol Corporation Basic Information And Sales Area

Table 47: The Lubrizol Corporation. Products Portfolio

Table 48: Terumo Corporation Basic Information And Sales Area

Table 49: Terumo Corporation. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Peripheral Intervention Drug-Eluting Devices Market Value (USD Million) By Region

Table 55: Global Peripheral Intervention Drug-Eluting Devices Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Peripheral Intervention Drug-Eluting Devices market size?

The Peripheral Intervention Drug-Eluting Devices market size was roughly USD 1.15 billion in 2023, reflecting demand across vascular clinics and hospitals worldwide. This valuation incorporates balloon catheters, stents, and coating technologies used to treat peripheral artery disease.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, expanding the market to approximately USD 2.0 billion by the end of the forecast period. Growth is driven by aging populations and rising prevalence of PAD.

3. Which factors are the primary drivers of market expansion?

Key drivers include increasing incidence of peripheral artery disease, adoption of drug‑eluting technologies that reduce restenosis, reimbursement reforms favoring value‑based care, and heightened physician awareness of minimally invasive treatment pathways that improve patient outcomes significantly.

4. What are the main challenges hindering market penetration?

Challenges comprise high upfront device costs, limited long‑term clinical data for newer coatings, procedural complexity requiring specialized training, and stringent regulatory pathways that can delay product launches. Additionally, competition from generic balloon angioplasty devices pressures pricing.

5. Which regions lead the Peripheral Intervention Drug-Eluting Devices market?

North America remains the leader, driven by robust healthcare infrastructure and early technology adoption, while Europe follows with strong reimbursement frameworks. Emerging growth is observed in APAC, especially China and India, where rising PAD prevalence fuels demand.

6. Who are the top companies competing in this market?

Leading players include Boston Scientific, Medtronic, Abbott Laboratories, Terumo Corporation, and Cardinal Health, each offering a portfolio of drug‑eluting balloons and stents. These firms invest heavily in R&D to launch next‑generation devices and secure strategic partnerships.

7. What future opportunities are emerging for market participants?

Opportunities arise from integrating bioresorbable polymers, personalized drug‑release kinetics, and AI‑guided deployment systems that enhance procedural precision. Expanding indications into chronic limb‑threatening ischemia and collaborating with diagnostic imaging firms also in the near future promise revenue diversification.

8. How is technology shaping the future outlook of the market?

Advanced coating nanotechnology, real‑time pressure sensors, and wireless telemetry are enabling smarter drug‑eluting devices that adapt to vessel dynamics. These innovations improve safety profiles, shorten hospital stays, and strengthen the market’s future outlook by attracting broader payer acceptance.

9. What regulatory considerations affect product launch timelines?

Companies must navigate FDA Class III pre‑market approval, EU MDR conformity assessments, and region‑specific clinical trial requirements. Post‑market surveillance obligations and evolving guidance on polymer safety can extend time‑to‑market, making regulatory strategy a critical component of commercialization plans.

Contact for Full Report

Loading report content...

Which Companies Lead the Peripheral Intervention Drug-Eluting Devices Market in 2026?

Market Snapshot

Peripheral Intervention Drug-Eluting Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Peripheral Intervention Drug-Eluting Devices Segmentation

Peripheral Intervention Drug-Eluting Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Peripheral Intervention Drug-Eluting Devices market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are the primary drivers of market expansion?

4. What are the main challenges hindering market penetration?

5. Which regions lead the Peripheral Intervention Drug-Eluting Devices market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for market participants?

8. How is technology shaping the future outlook of the market?

9. What regulatory considerations affect product launch timelines?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Peripheral Intervention Drug-Eluting Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Peripheral Intervention Drug-Eluting Devices Segmentation

Peripheral Intervention Drug-Eluting Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Peripheral Intervention Drug-Eluting Devices market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are the primary drivers of market expansion?

4. What are the main challenges hindering market penetration?

5. Which regions lead the Peripheral Intervention Drug-Eluting Devices market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for market participants?

8. How is technology shaping the future outlook of the market?

9. What regulatory considerations affect product launch timelines?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation